▲ Peaking
Business
Summit Packs A Punch For Merck's Keytruda
Summit Therapeutics and Akeso report that their cancer drug ivonescimab clears the overall survival bar in a Phase 3 trial.
Akeso
1 trends tracked about this subject — the full history, oldest to newest below.